Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk.
Canagliflozin
Dapagliflozin
Empagliflozin
Fracture
Sodium-glucose co-transporter-2 inhibitors
Type 2 diabetes mellitus
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
09
10
2019
pubmed:
18
11
2019
medline:
18
11
2019
entrez:
18
11
2019
Statut:
ppublish
Résumé
Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (CANVAS), a large randomized controlled trial (RCT) in patients with established cardiovascular disease or multiple cardiovascular risk factors, created concern. In the present review, we summarize the data regarding the association between SGLT2 inhibitors and fracture risk in patients with T2DM. In contrast to the findings reported in CANVAS, canagliflozin did not affect the risk of fracture in a more recent, large RCT in patients with diabetic nephropathy. In addition, empagliflozin and dapagliflozin, other members of this class, also do not appear to affect the incidence of fracture. Moreover, there is no clear pathogenetic mechanism through which SGLT2 inhibitors increase the risk for fractures. Therefore, available data are inconclusive to attribute to these drugs a direct responsibility for bone fractures.
Identifiants
pubmed: 31734830
doi: 10.1007/s13300-019-00724-w
pii: 10.1007/s13300-019-00724-w
pmc: PMC6965547
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
7-14Références
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Osteoporos Int. 2005 Dec;16(12):1713-20
pubmed: 15940395
Pharmacotherapy. 2017 Apr;37(4):481-491
pubmed: 28102030
Drugs. 2014 Apr;74(5):611-7
pubmed: 24668021
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669938
Osteoporos Int. 2012 Feb;23(2):635-41
pubmed: 21424265
Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):73-79
pubmed: 27898586
Bone. 2007 May;40(5):1352-60
pubmed: 17321229
Ther Adv Endocrinol Metab. 2013 Aug;4(4):122-8
pubmed: 23997931
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Lancet Diabetes Endocrinol. 2015 Jan;3(1):8-10
pubmed: 25523498
Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73
pubmed: 30559106
Drugs. 2014 Jun;74(8):939-44
pubmed: 24848755
Diabetes Metab. 2019 Oct;45(5):436-445
pubmed: 30738154
Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102
pubmed: 30559235
Drugs. 2014 Jun;74(8):945-50
pubmed: 24848756
J Bone Metab. 2016 Nov;23(4):183-190
pubmed: 27965939
Endocr Res. 2018 Feb;43(1):29-38
pubmed: 28972408
Nat Rev Endocrinol. 2012 Jan 17;8(5):276-86
pubmed: 22249518
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Gene. 2005 Nov 21;361:38-56
pubmed: 16183214
J Clin Endocrinol Metab. 2012 Jan;97(1):234-41
pubmed: 22031520
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
JAAPA. 2018 Jun;31(6):35-40
pubmed: 29846314
Osteoporos Int. 2006;17(7):986-95
pubmed: 16552468
J Clin Endocrinol Metab. 2008 Mar;93(3):1013-9
pubmed: 18160470
Diabetes Metab Res Rev. 2019 Oct;35(7):e3170
pubmed: 30983141
Annu Rev Med. 2010;61:91-104
pubmed: 20059333
Annu Rev Med. 2015;66:255-70
pubmed: 25341005
Osteoporos Int. 2005 Dec;16(12):1506-12
pubmed: 15824889
J Bone Miner Res. 2009 Apr;24(4):702-9
pubmed: 19049338
Rev Endocr Metab Disord. 2015 Jun;16(2):149-56
pubmed: 25669441
Indian J Endocrinol Metab. 2016 Nov-Dec;20(6):846-852
pubmed: 27867890
Adv Ther. 2017 Jul;34(7):1707-1726
pubmed: 28631216
Endocr J. 2006 Aug;53(4):503-10
pubmed: 16829706
Drugs. 2018 Mar;78(4):513-519
pubmed: 29476348